STRENGTHENING THE PATIENT VOICE IN HEALTH CARE

The Health Outcomes Observatory project (H2O) brings together the public and private sectors to create an unprecedented, standardised data governance and infrastructure system across Europe to incorporate patients’ opinions and preferences in decisions affecting their individual health care and those of the entire patient community.

With H2O infrastructure and tools, patients will be able to measure their outcomes in a standardised way, whilst keeping full control of their data. Ultimately, this framework of Observatories aims to foster innovation in health care in Europe and beyond to deliver better outcomes for all.  



Find out more about the Observatories

H2O vision 

Data governed and managed by the Health Outcomes Observatories will be accessed by patients and their health care providers to promote a richer and fruitful dialogue between patient and health care professionals based on meaningful information.

H2O aims to create a robust data governance model that gives patients control of their data and enables ethical, secure analysis of the data when patients consent to this, in the interest of society, science and patient care. Standardised and structured health data will be available for analysis in order to:

  • enhance health research prospects
  • promote the development of new treatments that reflect outcomes reported by patients
  • sustain more efficient healthcare systems
The H2O project will make a difference in health care. Discover how




Newsletter

Sign up to stay informed

ACKNOWLEDGEMENT

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.

About IMI

The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/

Legal notice